Abbott India Appoints Murari Ranganathan as Commercial Director

The Board of Directors of Abbott India Limited has approved the appointment of Murari Ranganathan as Commercial Director, Women’s Health, Metabolics, and International Business, with effect from May 2, 2024. He will be part of the senior management team at the company.

Murari Ranganathan is currently Commercial Director, Abbott Specialty Care (ASC)—Diabetes and Derma at Abbott Healthcare. Ranganathan joined Abbott in 2010 as Head Sales, Medical Nutrition, and successfully transitioned to the Marketing Manager role in Specialty Care Metabolics and Urology in 2014. Over the years, he gained experience managing various geographies and therapies. Later, he was promoted to Associate Director of Vaccines at Abbott India Limited (AIL), and then he was given responsibility to lead the commercial businesses of Metabolics and Miliana at AIL. After his successful stint in AIL, he was appointed Associate Director, ASC-Diabetes, and was then promoted to Commercial Director, ASC – Diabetes and Derma. In the past, he has worked with organisations like Baxter, Novo Nordisk, and Torrent Pharma. He has a bachelor in physics and mathematics from Bangalore University and has completed his postgraduate diploma in marketing from St. Joseph College of Business Administration, Bangalore.